Replimune Group (NASDAQ:REPL) Earns Buy Rating from HC Wainwright

Replimune Group (NASDAQ:REPL)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $17.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 53.85% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the stock. Roth Mkm began coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target for the company. JPMorgan Chase & Co. increased their price objective on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Finally, Roth Capital raised Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Replimune Group currently has an average rating of “Buy” and a consensus target price of $16.80.

Replimune Group Stock Performance

Shares of REPL opened at $11.05 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. Replimune Group has a 1 year low of $4.92 and a 1 year high of $12.97. The firm has a fifty day moving average of $11.50 and a 200-day moving average of $9.66. The company has a market cap of $756.04 million, a price-to-earnings ratio of -3.62 and a beta of 1.19.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. As a group, equities analysts anticipate that Replimune Group will post -3.02 earnings per share for the current year.

Insider Activity at Replimune Group

In related news, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now owns 109,885 shares in the company, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 8.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Replimune Group

Institutional investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC lifted its holdings in shares of Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after buying an additional 4,946 shares during the last quarter. Point72 DIFC Ltd acquired a new position in Replimune Group in the 2nd quarter valued at approximately $57,000. Erste Asset Management GmbH acquired a new position in shares of Replimune Group in the third quarter valued at $133,000. Arizona State Retirement System bought a new position in shares of Replimune Group during the 2nd quarter worth about $108,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Replimune Group by 82.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock worth $144,000 after purchasing an additional 5,926 shares during the period. 92.53% of the stock is currently owned by institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.